About Aderis Pharma
Aderis Pharma is a Healthcare company based in Hopkinton (United States) founded in 1994, and was acquired by Schwarz Pharma in July 2005. Aderis Pharma has raised $45 million across 2 funding rounds from investors including Temasek, CDIB Capital Group and Schwarz Pharma. Its chief executive, as recorded, is Peter Savas. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its competitors include Biogen, Denali Therapeutics and Nimbus Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Developer of small molecule drug candidates for the central nervous system, cardiovascular, and inflammatory diseases. The company is focused on developing solutions for Parkinsons disease, restless leg syndrome, cardiac image stress testing, atrial fibrillation, and wound healing. The lead product was Rotigotine which is a selective, non-ergolinic D3D2 receptor agonist for the treatment of Parkinsons disease and Restless Legs Syndrome.
- Headquarters Hopkinton, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website aderis.com
- Acquired by Schwarz Pharma (Jul 2005)
- Total Equity Funding$45M (USD)
in 2 rounds
- InvestorsTemasek
& 8 more
- Acquired bySchwarz Pharma
(Jul 2005)
Funding Insights of Aderis Pharma
Aderis Pharma has successfully raised a total of $45M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $45M
- Total Rounds 2
- First Round $45M
(Oct 2001)
- Investors Count 8
All 2 funding rounds of Aderis Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2026 | Series C | – | – | ||
| Oct 2001 | $45M | Series C | – | – |
9 investors in total: 9 institutional.
Investors in Aderis Pharma
Aderis Pharma has secured backing from 9 investors, including venture fund investors. Prominent investors backing the company include Temasek, CDIB Capital Group and Schwarz Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment opportunities in biotechnology are facilitated by this trust. | ibtplc.com | London, United Kingdom | ||
Stage-agnostic life sciences-focused VC firm investing in North America & Europe | neomed.net | Oslo, Norway | ||
An investment platform is provided for diverse sectors and geographies. | 1974 | temasek.com.sg | Singapore, Singapore | |
Biomedical investment financing and active management services. | sanderling.com | |||
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
Sector-agnostic investments are made in early-stage Asia Pacific startups. | 1959 | cdibcapitalgroup.com | Taipei, Taiwan | |
| mdscapital.com | ||||
| three.vc | ||||
Drugs for cardiovascular system, gastrointestinal tract ,asthma, neurology and urology | 1946 | schwarzpharma.com | Monheim, Germany |
Investor details for Aderis Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aderis Pharma
1 people are tracked at Aderis Pharma (1 in leadership).
| Name | Role | Group |
|---|---|---|
Peter Savas | CEO | Leadership |
Complete people profiles for Aderis Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Aderis Pharma
4 dated milestones of Aderis Pharma across 32 years, from founding to its latest funding, stage changes and deals.
- Founded Aderis Pharma is founded.
- Funding First funding round of $45.0M.
- Exit Acquired by Schwarz Pharma.
- Funding Latest funding round, Series C,.
Competitors of Aderis Pharma
Aderis Pharma has 3 listed competitors in our database, 3 of them funded. They include Biogen, Denali Therapeutics and Nimbus Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. |
Detailed competitors of Aderis Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Aderis Pharma (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aderis Pharma
Complete news archive for Aderis Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aderis Pharma
Aderis Pharma was founded in 1994 and raised its 1st funding round 7 years after it was founded.
Aderis Pharma is headquartered in Hopkinton, United States. It is registered at Hopkinton, Massachusetts, United States.
Peter Savas is the CEO of Aderis Pharma, as recorded in our data.
Aderis Pharma is a funded company, having raised a total of $45M across 2 funding rounds to date. The company's 1st funding round was a Series C of $45M, raised on Oct 2001.
Developer of small molecule drug candidates for the central nervous system, cardiovascular, and inflammatory diseases. The company is focused on developing solutions for Parkinsons disease, restless leg syndrome, cardiac image stress testing, atrial fibrillation, and wound healing. The lead product was Rotigotine which is a selective, non-ergolinic D3D2 receptor agonist for the treatment of Parkinsons disease and Restless Legs Syndrome.
Aderis Pharma's top competitors include Nimbus Therapeutics, Denali Therapeutics and Biogen.
Aderis Pharma has 9 investors. Key investors include Temasek, CDIB Capital Group, Schwarz Pharma, International Biotechnology Trust, and NeoMed.
Yes. Aderis Pharma was acquired by Schwarz Pharma in July 2005.